Intas Pharma to be the first to launch pegfilgrastim biosimilar in Europe

31 July 2018

Indian biopharma company Intas Pharmaceuticals' wholly-owned subsidiary Accord Healthcare is set to be the first integrated player to launch a pegfilgrastim biosimilar across Europe after nearly being given the regulatory green light for Pelgraz (pegfilgrastim).

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) last Friday issued a positive opinion for Accord's Pelgraz (pegfilgrastim), pegylated granulocyte-colony stimulating factor (G-CSF) biosimilar in Europe. The current market for pegfilgrastim, sold by Amgen’s (Nasdaq: AMGN) as Neulasta, in the European Union is about 500 million euros ($586 million) a year.

Intas Pharmaceuticals will manufacture Pelgraz in its own state-of-the-art production facility. Intas has deep experience with biosimilar medicines. As of July 2018, Intas has 12 different biosimiliars approved in various markets across the world. This reflects a long-standing commitment of Intas to develop, manufacture and market biosimilars.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK